Irinotecan Hydrochloride Hospira Uk

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hydrochloride Hospira Uk, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is employed in the treatment of colorectal cancer, including metastatic disease, in adult patients, often as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Hydrochloride Hospira Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, including research institutions, providing reliable sourcing and regulatory support for global cancer care programs.

Irinotecan is a topoisomerase I inhibitor employed in the management of colorectal cancer and its advanced forms.

Colorectal cancer: used in combination regimens to improve tumor response rates and overall survival in patients with locally advanced disease. Metastatic colorectal cancer: incorporated into standard first‑line or second‑line chemotherapy protocols to extend progression‑free survival and manage disease spread. Adjuvant colorectal cancer: administered after surgical resection to reduce the risk of disease recurrence and support long‑term remission.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal medication. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea: may occur during or after infusion. - Vomiting: can be managed with antiemetics. - Alopecia: hair loss that is usually reversible. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Febrile neutropenia: fever accompanying neutropenia, indicating possible infection. - Intestinal perforation: rare but life‑threatening gastrointestinal injury. - Severe allergic reaction: anaphylaxis or hypersensitivity requiring immediate treatment. - Hepatic toxicity: elevated liver enzymes or liver dysfunction. - Severe dehydration: secondary to intense diarrhea and fluid loss.

When using Irinotecan, careful monitoring and specific precautions are essential to minimize risks. - Dose adjustment: assess hepatic function before initiating therapy and adjust dose accordingly. - Monitor blood counts: perform regular complete blood counts to detect neutropenia early. - Hydration: ensure adequate fluid intake to mitigate severe diarrhea and prevent dehydration. - Avoid concurrent strong CYP3A4 inhibitors: these may increase Irinotecan exposure and toxicity. - Pregnancy: contraindicated unless the potential benefit justifies the risk; limited safety data are available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several drugs, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Irinotecan toxicity. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): can raise SN‑38 levels and risk severe neutropenia. - Concurrent high‑dose myelosuppressive agents: heightens risk of profound bone‑marrow suppression. - High‑dose irinotecan with other topoisomerase I inhibitors: may cause additive toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Irinotecan effectiveness. - Anticholinergic agents: may worsen constipation when diarrhea resolves. - Warfarin: monitor INR closely due to potential increased bleeding risk.